New drug IMC-001 targets Hard-to-Treat cancers in small trial
NCT ID NCT06365840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests the drug IMC-001 in 30 adults with advanced solid tumors that have a high number of genetic mutations (TMB-H). Participants receive the drug by IV every two weeks. The main goal is to see if the drug shrinks tumors. Researchers will also monitor side effects and how long the benefit lasts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMC-001 (a drug given by IV infusion every 2 weeks)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced solid tumors that have a high number of genetic mutations.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTOLOGICALLY OR CYTOLOGICALLY PROVEN METASTATIC OR LOCALLY ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center
RECRUITINGGoyang, South Korea
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, South Korea
-
Severance Hospital
RECRUITINGSeoul, South Korea